PL3134119T3 - Leczenie nowotworu - Google Patents

Leczenie nowotworu

Info

Publication number
PL3134119T3
PL3134119T3 PL15729222T PL15729222T PL3134119T3 PL 3134119 T3 PL3134119 T3 PL 3134119T3 PL 15729222 T PL15729222 T PL 15729222T PL 15729222 T PL15729222 T PL 15729222T PL 3134119 T3 PL3134119 T3 PL 3134119T3
Authority
PL
Poland
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Application number
PL15729222T
Other languages
English (en)
Inventor
Jean-Francois Andre MARTINI
Jamal Christo TARAZI
James Andrew WILLIAMS
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of PL3134119T3 publication Critical patent/PL3134119T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Oncology (AREA)
PL15729222T 2014-04-24 2015-04-16 Leczenie nowotworu PL3134119T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461983951P 2014-04-24 2014-04-24
PCT/IB2015/052796 WO2015162532A1 (en) 2014-04-24 2015-04-16 Cancer treatment
EP15729222.8A EP3134119B1 (en) 2014-04-24 2015-04-16 Cancer treatment

Publications (1)

Publication Number Publication Date
PL3134119T3 true PL3134119T3 (pl) 2018-12-31

Family

ID=53398149

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15729222T PL3134119T3 (pl) 2014-04-24 2015-04-16 Leczenie nowotworu

Country Status (23)

Country Link
US (2) US20170184602A1 (pl)
EP (1) EP3134119B1 (pl)
JP (1) JP6603474B2 (pl)
KR (1) KR101943177B1 (pl)
CN (1) CN106233143B (pl)
AR (1) AR100169A1 (pl)
AU (3) AU2015249513A1 (pl)
BR (1) BR112016024143A2 (pl)
CA (1) CA2946362C (pl)
CY (1) CY1120731T1 (pl)
DK (1) DK3134119T3 (pl)
ES (1) ES2691213T3 (pl)
HU (1) HUE040167T2 (pl)
IL (1) IL247859B (pl)
MX (1) MX375794B (pl)
PL (1) PL3134119T3 (pl)
PT (1) PT3134119T (pl)
RU (1) RU2651469C1 (pl)
SG (1) SG11201607918TA (pl)
SI (1) SI3134119T1 (pl)
TR (1) TR201815682T4 (pl)
TW (1) TWI568439B (pl)
WO (1) WO2015162532A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6945199B2 (ja) 2017-05-19 2021-10-06 国立大学法人山口大学 アキシチニブの薬物動態判定方法及びアキシチニブの薬物動態に基づくアキシチニブによる治療効果予測方法
KR102767594B1 (ko) 2018-07-12 2025-02-12 코버스 파마슈티칼스, 인크. 아데노신 경로 활성화를 갖는 암의 검출 및 치료 방법
EP3820522A4 (en) 2018-07-12 2022-05-18 Corvus Pharmaceuticals, Inc. METHODS OF DETECTION AND THERAPY OF CANCER WITH ACTIVATION OF THE ADENOSIN SIGNALING PATHWAY
US11409549B2 (en) 2018-10-15 2022-08-09 AIble Inc. Interface for generating models with customizable interface configurations
US10936768B2 (en) * 2018-10-15 2021-03-02 Aible, Inc. Interface for visualizing and improving model performance
US10586164B1 (en) 2018-10-15 2020-03-10 AIble Inc. Interface for visualizing and improving model performance
WO2021076852A1 (en) * 2019-10-17 2021-04-22 Board Of Regents, The University Of Texas System Small extracellular vesicle-associated vegf as a predictor for therapeutic responses
EP4522991A1 (en) * 2022-05-11 2025-03-19 Deutsches Krebsforschungszentrum Use of bmmf1 rep protein as diagnostic marker for lung cancer
CA3252712A1 (en) * 2022-05-11 2023-11-16 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts USE OF REP BMMF1 PROTEIN AS A DIAGNOSTIC MARKER FOR PANCREATIC CANCER AND TYPE 2 DIABETES
US20260035476A1 (en) * 2022-07-28 2026-02-05 The Board Of Regents Of The University Of Oklahoma Biomarkers, diagnostic methods, treatments, and therapeutics for autoimmune disorders and diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004284434A1 (en) 2003-10-16 2005-05-06 Genomic Health, Inc. qRT-PCR assay system for gene expression profiling
EP1737980A2 (en) * 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
CN101506351A (zh) * 2005-10-21 2009-08-12 拜尔健康护理有限责任公司 用于癌症预测和预后及监测癌症治疗的方法
WO2007067500A2 (en) * 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
RU2480769C2 (ru) * 2006-07-28 2013-04-27 Новартис Аг Применение белка с меланома-ингибирующей активностью (миа) в качестве раннего индикатора терапевтического ответа при меланоме
US8338433B2 (en) * 2006-11-22 2012-12-25 University Of Georgia Research Foundation, Inc. Tyrosine kinase inhibitors as anti-kinetoplastid agents
US10095829B2 (en) * 2009-07-08 2018-10-09 Worldwide Innovative Network Computer implemented methods of treating lung cancer
JP5606537B2 (ja) * 2009-09-17 2014-10-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌患者における診断使用のための方法及び組成物
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
WO2012052757A1 (en) * 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
JP2014503500A (ja) * 2010-11-18 2014-02-13 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
WO2013052652A1 (en) * 2011-10-04 2013-04-11 Erard Gilles Methods and systems for identifying and treating anti-progestin sensitive tumors
BR112014017320A2 (en) * 2012-01-13 2018-05-29 Genentech, Inc method for determining whether a patient is prone to respond to treatment with a vegf antagonist, method for optimizing the therapeutic efficacy of a vegf antagonist, method for selecting a therapy, method for identifying a biomarker, and method for diagnosing an angiogenic disorder

Also Published As

Publication number Publication date
CN106233143A (zh) 2016-12-14
AU2015249513A1 (en) 2016-10-06
MX375794B (es) 2025-03-07
RU2651469C1 (ru) 2018-04-19
EP3134119A1 (en) 2017-03-01
CY1120731T1 (el) 2019-12-11
PT3134119T (pt) 2018-11-07
SI3134119T1 (sl) 2018-11-30
IL247859B (en) 2020-07-30
SG11201607918TA (en) 2016-11-29
MX2016013910A (es) 2017-01-11
WO2015162532A1 (en) 2015-10-29
TW201545747A (zh) 2015-12-16
AU2020200237A1 (en) 2020-02-06
AU2018203086A1 (en) 2018-05-24
AR100169A1 (es) 2016-09-14
TWI568439B (zh) 2017-02-01
IL247859A0 (en) 2016-11-30
TR201815682T4 (tr) 2018-11-21
CA2946362C (en) 2019-03-12
US20190331687A1 (en) 2019-10-31
KR20160134817A (ko) 2016-11-23
BR112016024143A2 (pt) 2017-08-15
HK1231561A1 (zh) 2017-12-22
DK3134119T3 (en) 2018-10-22
EP3134119B1 (en) 2018-08-22
CN106233143B (zh) 2020-01-21
ES2691213T3 (es) 2018-11-26
JP6603474B2 (ja) 2019-11-06
CA2946362A1 (en) 2015-10-29
JP2015210268A (ja) 2015-11-24
HUE040167T2 (hu) 2019-02-28
KR101943177B1 (ko) 2019-01-28
US20170184602A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
IL296080B1 (en) Method for treating cancer
IL255261A0 (en) Methods for treating cancer
DK3240801T3 (da) Kombinationstumorimmunterapi
IL251890A0 (en) Combination immunotherapy approach for treatment of cancer
HUE054012T2 (hu) Kombinációs terápia rák ellen
DK3590543T3 (da) Medicinsk forbinding
PL3197456T3 (pl) Leczenie nowotworów
DE102015102730B8 (de) Verbinder
DK3231444T3 (da) Ny behandling
KR20180084772A (ko) 암 치료를 위한 조합 치료법
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
EP3546020A4 (en) CANCER TREATMENT APPARATUS
PL3134119T3 (pl) Leczenie nowotworu
EP3413927A4 (en) CANCER THERAPY
DK3576740T3 (da) Cancerbehandling
IL251903B (en) Apilimod for use in the treatment of colorectal cancer
EP3576791A4 (en) CALRETICULIN-MEDIATION CANCER TREATMENT
HUE046894T2 (hu) Anamorelinen alapuló gyógyászati kezelések
DK3393478T3 (da) Kombinationsterapi
EP3362091A4 (en) COMBINATION THERAPY
IL246558A0 (en) Novel methods for treating cancer
DK3302478T3 (da) Pac-1 kombinations behandling
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
DK3407909T5 (da) Cancerbehandling
DE112015001144A5 (de) Therapievorrichtung